2022
898-P: Impact of Switching to a High-Deductible Health Plan on Patients’ Out-of-Pocket Expenditures for Glucose-Lowering Drugs
JIANG D, HERRIN J, VAN HOUTEN H, MCCOY R. 898-P: Impact of Switching to a High-Deductible Health Plan on Patients’ Out-of-Pocket Expenditures for Glucose-Lowering Drugs. Diabetes 2022, 71 DOI: 10.2337/db22-898-p.Peer-Reviewed Original ResearchHigh-deductible health plansGlucose-lowering drugsHDHP enrolleesOOP expensesHealth outcomesPocket expenditureHealth plansBurden of treatmentCostly health conditionsPoor health outcomesDeductible Health PlansGlycemic managementHigh-value careKidney diseaseDiabetes managementOOP costsValue careOOP expenditurePrescription drugsDiabetesHealth conditionsDirect costsDrugsEnrolleesHealth insurance
2006
Door-to-drug and door-to-balloon times: Where can we improve? Time to reperfusion therapy in patients with ST-segment elevation myocardial infarction (STEMI)
Bradley EH, Herrin J, Wang Y, McNamara RL, Radford MJ, Magid DJ, Canto JG, Blaney M, Krumholz HM. Door-to-drug and door-to-balloon times: Where can we improve? Time to reperfusion therapy in patients with ST-segment elevation myocardial infarction (STEMI). American Heart Journal 2006, 151: 1281-1287. PMID: 16781237, DOI: 10.1016/j.ahj.2005.07.015.Peer-Reviewed Original ResearchConceptsST-segment elevation myocardial infarctionPatients' clinical characteristicsBalloon timeClinical characteristicsDrug timeMyocardial infarctionProportion of patientsElevation myocardial infarctionHospital-level variationTreatment of patientsCross-sectional analysisHigh performing hospitalsReperfusion therapyNational registryHospitalPatientsRegression modelingECGDrugsInfarctionHierarchical regression modelingHospital performanceImportant quality indicatorMinutesGeometric mean